Increased endogenous endothelin activity contributes to vascular dysfunction in obesity and diabetes. We report augmented effects of BQ123, an antagonist of type A endothelin receptors, to reduce systemic blood pressures in diabetic subjects compared to obese and lean control subjects. These differences were not explained by crossgroup differences in obesity or baseline blood pressure, suggesting contributions from other features of the diabetic state.
We and others have recently reported evidence for increased endogenous activity of endothelin-1 (ET-1) in skeletal muscle resistance vessels in obesity and diabetes. 1, 2 This excess endothelin tone appears to contribute to impaired endothelium-dependent vasodilation. 1 Another feature of obesity and diabetes is an increase in the prevalence of hypertension, and more generally a rightward shift of the distribution of blood pressures in affected individuals. Endothelin plays an important role in a variety of forms of human hypertension. 3 Given that local regulation of vascular tone in peripheral resistance vessels impacts systemic blood pressure, it is possible that the observed excess peripheral vascular ET-1 tone in obesity and diabetes contributes to this net increase in blood pressure. This has not been systematically studied to date.
In previous reports from our laboratory, 1, 4 we noted an effect of femoral arterial infusions of BQ123 on mean arterial pressure, and the observed leg blood flow data were adjusted for these changes and presented as leg vascular resistance. We have not previously presented the blood pressure data from these studies, and here we present these data in detail, including separate evaluations of systolic, diastolic and pulse pressure changes.
We studied 13 lean, 16 obese and eight type 2 diabetic subjects. Obesity was defined using body mass index (BMI) cut points of X26 kg/m 2 for men or X28 kg/m 2 for women. Subjects with type-2 diabetes mellitus (DM2) were included on the basis of either a historical diagnosis of DM2 confirmed on screening or a new diagnosis made on screening (according to American Diabetes Association (ADA) criteria). Subjects were excluded with frank hypertension (systolic blood pressure (SBP)4140 mm Hg/ diastolic blood pressure (DBP)490 mm Hg) or antihypertensive therapy, elevated serum lipids (total cholesterol 45.2 mmol/l, low-sensity lipoprotein 42.3 mmol/l or triglyceride 42.0 mmol/l), biochemical evidence of renal or hepatic dysfunction, or significant underlying medical conditions. Diabetic subjects with known microvascular disease, including prior evidence of microalbuminuria, were excluded. Diabetic subjects withheld oral hypoglycaemic agents for a minimum of 14 days before the study. This study was approved by the local Institutional Review Board, and all subjects gave written informed consent.
Studies were performed as described previously. 1, 4 In brief, following an overnight fast, the femoral vein and artery were cannulated allowing measurement of leg blood flow by thermodilution and direct intra-arterial measurement of blood pressure. Baseline measurements were obtained following X30 min of rest after the insertion of the catheters. ET-1 blockade was achieved with BQ123 (Clinalfa, Basel, Switzerland), a high-affinity competitive inhibitor of ET-1 type A receptors. 5 Under the original study design, the outcome of interest was the effect of endothelin antagonism on leg vascular function. Therefore, BQ123 was infused into the femoral artery, with measurements made after 90 min exposure to 1 mmol/min, and again following a further 30 min exposure to 3 mmol/min. Diabetic subjects were older on average (lean 3478 years; obese 34710; DM2 43710, P ¼ 0.05), and baseline blood pressures also differed across groups (SBP lean 126.279.5 mm Hg, obese 135.079.5, DM2 147.0715.2, P ¼ 0.004, DBP lean 70.975.7, obese 78.479.5, DM2 80.578.5, P ¼ 0.2). Obese and DM2 groups were otherwise matched for BMI, circulating free fatty acids, endothelin, insulin and lipids. 1, 4 In lean subjects, SBP fell by 3.371.8 and 5.171.4 mm Hg at low and high doses (P ¼ 0.010 and P ¼ 0.004, respectively; Figure 1) . A similar pattern was seen in obese subjects, (reductions of 1.1071.3 and 5.371.4 mm Hg, P ¼ 0.4 and P ¼ 0.002, respectively) and diabetic subjects, (reduction of 5.172.2 and 10.672.0 mm Hg, P ¼ 0.057 and P ¼ 0.001, respectively). Adjusting for differences in age, gender and race across groups, we found that high dose BQ123 infusion, but not low dose, produced differential changes from baselines across the three groups (P ¼ 0.041), with a greater response in diabetic subjects evident on pairwise analysis (Po0.05).
DBPs fell more uniformly across the three groups. Reductions in lean subjects were 4.571.4 and 5.670.9 mm Hg (low and high doses, P ¼ 0.008 and Po0.001, respectively); obese subjects 3.071.0 and 5.971.1 mm Hg (low and high doses, P ¼ 0.01 and Po0.001, respectively); diabetic subjects 5.371.3 and 6.270.7 mm Hg (low and high doses, P ¼ 0.005 and 0.002, respectively). This effect was significant for each subject group individually (Figure 1) , and was greater with the higher infusion rate. There was no statistical difference in the DBP response across groups.
Pulse pressure was unchanged with either dose of BQ123 in lean and obese subjects, reflecting symmetric reductions in SBP and DBP at both doses. However, in the type 2 diabetic subjects, the pulse pressure was significantly reduced from baseline at high-dose BQ123 (P ¼ 0.028).
A small but significant increase in heart rate from 64.2710.2 to 66.9711.6 beat per minute was seen with the high-dose BQ123 infusion (Po0.001), but was not evident at the lower infusion rate. This was not different across groups (P ¼ 0.3).
We undertook multivariate analyses in order to assess whether these differences arose simply owing to baseline differences across groups. Potential determinants of the reduction in SBP which were entered into the model included baseline SBP and DBP, age, lipid profile, BMI, gender, race and subject group (lean, obese and diabetic). The effect of subject group alone (F-statistic 5.63, P ¼ 0.01, r 2 0.278) was much more powerful than that of baseline blood pressure alone (F-statistic 2.81, P ¼ 0.10, r 2 0.06), and modelling using the combination of these two effects showed no separate contribution of baseline blood pressure once subject group was included. Including obesity parameters together with group improved the model (overall r 2 0.499, P ¼ 0.01), strengthening the contribution of subject group (F-statistic 7.20, P ¼ 0.006) and further weakening the contribution of baseline blood pressure to the modelling (F-statistic 0.06, P ¼ 0.94). The addition of lipid parameters was noncontributory.
These results are consistent with prior reports that endothelin makes important contributions to the regulation of systemic blood pressures, [6] [7] [8] and suggest that endothelin's contributions to altered regulation of peripheral vascular function also have an impact on elevated blood pressure particularly in DM2. The specific effect observed in diabetic subjects on pulse pressure reflects a proportionally greater reduction in systolic than diastolic pressure. This in turn may imply targeted benefits in diabetesassociated complications, which relate most closely to systolic or pulse pressure, such as stroke.
The origin of these differences between obese and diabetic subjects is unclear. In vitro, a number of metabolic variables exert effects on endothelin production or action, including glucose, 9 insulin 10 and free-fatty acids. 11 The in vivo determinants of ET-1 production and action have not been extensively explored. Certainly, hyperglycaemia is the most obvious metabolic difference between obese and diabetic subjects. The detrimental effects of hyperglycaemia on the vasculature in vivo have been attributed in large part to stimulation of oxidative stress, 12 but the present results suggest that concurrent direct or indirect effects on ET-1 production or action may also be important.
The current results represent a post hoc analysis of data collected for studies of leg vascular function, and in contrast to other reports the antagonist was infused via the femoral artery limiting any direct comparisons with prior literature. Also, as blood pressure determinants were not the primary focus of the original study, we have not collected other relevant data such as measures of sympathetic system activation, or measures of urinary sodium handling. In this light, these observations should be taken as hypothesis generating. Hypotheses to be prospectively tested might include whether these observations can be replicated using systemic, as opposed to local arterial, infusions of the antagonist; whether such blood pressure effects require specific versus nonspecific endothelin receptor antagonism; and ultimately whether these results can be translated to clinical trial observations using oral doses of endothelin antagonists. Nevertheless, the current observations point to an important effect of peripheral actions of endothelin as a contributor to blood pressure regulation in all subjects, and suggest an augmented blood pressure effect of endothelin in subjects with DM2. Figure 1 Blood pressure responses to BQ123. Stars denote significant changes from baseline within the subject group (Po0.05). Results of adjusted two-way analysis of variance comparing the change in blood pressure with BQ123 across the three groups are presented across the top of each figure. By subsequent pairwise analysis, subjects with diabetes responded differently than the other groups for both SBP and pulse pressure. DBP ¼ diastolic blood pressure; SBP ¼ systolic blood pressure.
